Responses following mTOR inhibition have been observed in patients with relapsed/refractory T-cell NHL, and by promoting autophagy and ICD may be rationally combined with both HDAC inhibitors and CPB [101, 103–105]. The gene discussed is MTOR; the disease is T-cell non-Hodgkin lymphoma.